Chemical Exposure and the Brain
Environmental toxicants can have profound effects on brain function. Even the smallest exposures can cause significant neurological deficits. These can be sudden and severe or delayed and more gradual, manifesting, for instance, as neuropsychiatric disorders decades after exposure [1] . Assessment of delayed neurological effects of exposure is challenging. First, the lag between exposure and symptom onset limits the usefulness of minimally invasive measures (e.g., blood, urine) that provide little information on past or cumulative exposure. Second, the brain is physiologically compartmentalized and direct assessment of toxicant penetration into the brain itself is limited to invasive measurements. In this Forum, we highlight the need to treat the brain as a unique exposure entity in the context of environmental factors and disease risk. We argue that cross-disciplinary efforts, embedding analytical tools into epidemiological studies, are needed to better understand the long-term risks of environmental exposures for brain health and accelerate public health policy changes where appropriate.
Neuroexposomics: A Data-Driven Approach for Integrated 'Omics'
Analyses of Brain-Environment Interactions
The exposome was proposed by Christopher Wild in 2005 as a conceptual integration of burgeoning omic sciences [e.g., metabolomics (see Glossary), transcriptomics, proteomics] with exposure biology to complement the growing use of genomics in epidemiology [2] . brain ( Figure 1 ). In the following, we discuss how neuroexposomic workflows can be applied in the context of three scenarios. The first examines how derailing of early brain development via toxicant exposure may predispose individuals to neurodevelopmental disorders. The second places neuroexposomics in the context of 'multi-hit' hypotheses for disease susceptibility. The third scenario examines the concept of 'sleeper effects', where exposure might impact the emergence of neurodegenerative disorders much later in life.
Metabolomics

Interpreting Critical Windows of Susceptibility in Neurodevelopment
Vulnerability to environmental toxicants begins at conception and extends through gestation, parturition, infanthood, adolescence, and into adulthood. Although traditionally defined by dynamic processes occurring at the cellular and system level rather than specific exposure risk, critical windows of neurodevelopment can also be delineated by heightened susceptibility to even short-term exposure to chemicals that are otherwise considered harmful at any life stage [1] . The duration of critical windows varies depending on both the chemical species and the neurodevelopmental stages affected[ 1 3 3 _ T D $ D I F F ] , and the consequences of exposure during these periods can be neuropathologies with latency periods extending well beyond childhood. Rapid brain growth occurring in the first 1000 days (conception to roughly second birthday) has drawn the most attention with respect to long-term exposure effects, although appreciation of the influence of biochemical and lifestyle factors on neurodevelopment extending into adolescence is increasing [4] . In many cases it is timing rather than level of exposure that is the largest determinant of delayed-onset effects.
Retrospective association of neurodevelopmental outcomes with a specific historical exposure is hampered by the scarcity of suitable biomarkers. One innovative method involves microchemical analysis of deciduous teeth, which begin calcifying in the second trimester and incorporate circulating toxicants in incremental growth lines [ 1 3 4 _ T D $ D I F F ] that can be used as a temporal record of exposure. However, methodological limitations of this approach highlight the risks in drawing parallels between low-level chemical exposure and divergent mechanisms of neurotoxicity and neurodevelopmental disorders with broad psychiatric phenotypes. For instance, in a study of 289 twins, pre-and postnatal lead exposure and zinc and manganese deficiency measured in teeth were associated with a discordant autism spectrum disorder (ASD) diagnosis in seven twin pairs [5] . Inferences regarding stressors that influence placental transfer of metals and divergent downstream effects of essential metal deficiencies on epigenetic modifications without mechanistic evidence or quantitative exposure levels limit meaningful conclusions. Additionally, control for potential neurodevelopmental comorbidities associated with chronic lead exposure (e.g., Bayley Scales of Infant Development scores) was unclear. This 
Critical Windows and the MultiHit Hypothesis of Psychosis and Schizophrenia
Multi-hit hypotheses accounting for a combination of genetic risk, environmental exposure, and lifestyle factors in the etiology of neurological disorders are increasingly used to explain individual susceptibility. For example, chronic Figure 1 . Designing a Neuroexposomic Workflow. 'Omics' disciplines can be integrated to measure the effects of chemical exposure (shown here using methylmercury as a classic example). Environmental monitoring of both biotic and abiotic sources traces anthropogenic sources and routes of exposure, ideally indicating when environmental remediation is needed for persistent pollutants, while human biomonitoring assesses the amount of toxicant present in exposed individuals or cohorts at any one time. Metabolomics identifies excretion pathways, including clinical intervention as well as the detection and quantification of bloodbrain barrier-permeable species. In the CNS, approaches such as proteomics, lipidomics, and glycomics can be used to identify response factors and markers of neurotoxicity (most informative in postmortem tissue), whereas genomics, epigenomics, and transcriptomics can predict personalized genetic risk factors and responses. The duration, timing, and degree of exposure can produce a range of neurological effects, with phenomics used to characterize deviation from normal neurological function. Taken together, neuroexposomic workflows feed into the implementation of public health policy, which cycles back to improved environmental monitoring and human biomonitoring as the primary means for limiting exposure. . A recent commentary, by contrast, questioned two-hit models of schizophrenia, arguing that they are overly simplistic and downplay cumulative effects of biological, social, and environmental influences [8] . Given that such influences, while complex, are quantifiable and well defined, we propose that targeted longitudinal neuroexposomics frameworks can be designed to assess schizophrenia risk factors. One could envision a combination of the following assessments: (i) peripheral biofluid measurements employing metabolomics (postnatal vitamin D status, maternal nutrition), transcriptomics (endogenous retroviral activation, genetic risk), and proteomics (downstream dysfunctional cytokines) to monitor system-wide effects; (ii) standardized questionnaires and surveys on diet and lifestyle; (iii) neuropsychiatric assessments; and (iv) consensus diagnosis [ 1 4 0 _ T D $ D I F F ] per DSM criteria. The rapid expansion of the medicinal and recreational cannabis industry underscores the urgency of such prospective cohorts and necessitates the identification of individual risk as a harm-minimization strategy.
Neuroexposomics and Neurodegeneration
Genetic risk factors are directly implicated in a small percentage of neurodegenerative diseases. Most diseases are considered sporadic, in that molecular mechanisms of disease remain to be identified, and it is plausible that multi-hit scenarios involving genetic risk also apply to neurodegeneration. In contrast to schizophrenia, where the environment and its relationship to age of onset are better understood, the latency between exposure, molecular pathology, symptoms onset, and clinical diagnosis may be of the order of decades. Prospective cohorts are impractical [9] and the few proposed environmental risk factors are the subject of much debate. With that, much can be learned from postmortem studies with appropriate experimental design or through creative repurposing of existing cohorts.
As an example, Morris et al. used a targeted neuroexposomic approach as part of a broader longitudinal study of Alzheimer's disease [10] . Evidence supports an association between seafood consumption and neuroprotection, although concomitant bioaccumulation of mercury and effects on cognition may offset any benefit. Morris et al. aligned postmortem brain mercury levels with estimated long-chain fatty acid intake from seafood as well as neuropathology and APOE genotyping collected as part of the two-decade parent study. The authors showed that seafood intake increased brain mercury without affecting disease severity. While the APOE e4 allele carries a higher risk of Alzheimer's disease, Morris and colleagues found that e4 carriers consuming a moderate-seafood diet benefited from increased APOE-mediated transport of protective fatty acids across the blood-brain barrier. In a wider context, this illustrates how deleterious effects of a known neurotoxin can be offset by other, concomitant factors, in this case sharing a single origin -seafood consumption. [11] . This demonstrates how a welldesigned and validated model can be integrated with an epidemiological study without the need for direct sampling at the time of exposure. Further, it is an example of how the critical-window-of-susceptibility concept can be viewed as dependent on environmental and lifestyle factors as opposed to stages of brain development alone.
For sporadic forms of Parkinson's disease where direct causes of neuron loss are likely to involve a number of endogenous and external factors, elucidating potential environmental contributors is more challenging, particularly for those occurring during early life. Although these are still very much hypothetical and based primarily on animal studies, we direct the reader to our previous discussion of the challenges of and possible solutions for the study of postnatal iron overexposure as a risk factor for Parkinson's disease [9] .
Discovery Neuroexposomics
By 2030, it is estimated there will be over 100 000 registered compounds in the environment in the USA alone. While the majority are likely to be inert, only a fraction have been properly assessed for acute toxicity, let alone delayed neurological effects. A human-based exposomic approach to address a list of this scale is unrealistic. It is here that preclinical studies using cells and model organisms are crucial for: (i) evaluating potential public health risks; (ii) prioritizing deeper studies into risk factors; and (iii) justifying human monitoring. Between 2006 and 2013, only 12 chemicals were categorically identified as harmful to the human brain via epidemiological studies and even then only within terms of reference as neurodevelopmental impediments [12] . Several hundred compounds that exhibit developmental neurotoxicity in animals have not been examined in humans. There is, however, hope that compound screening in controlled laboratory settings will accelerate translation as turnkey analytical technologies with ever-improving sensitivity and specificity are taken up by neuroscientists, epidemiologists, and clinicians alike.
Concluding Remarks
Although the brain may not be as isolated as dogma previously suggested, we argue that it represents a unique [ 1 4 4 _ T D $ D I F F ] toxinexposure entity. The mechanisms of toxicity unique to long-lived neurons, in addition to the delayed functional consequences of even low-level exposure, can be considered largely independent from their external effects. The principles of a neuroexposomic workflow and examples we discussed here serve as a guide for future studies of the impact of chemical exposure on brain health, although how they are implemented should fully capitalize on the capabilities of emerging technologies specific to the study of the brain. Successful application in epidemiology is dependent on the same challenges identified by Wild when he introduced the exposome concept [2] : a need for greater collaboration across disciplines and a shift in the priorities of funding agencies that recognizes patience as a virtue when assessing the long-term neurological effects of chemical exposures.
